Add BrightSurf on Google Email

Chinese Medical Journal review illuminates the multifaceted role of LRRK2 in health and disease

The review highlights LRRK2's diverse cellular functions and pathogenic mechanisms in various diseases, including Parkinson's disease and inflammatory disorders. Therapeutic strategies targeting LRRK2, such as kinase inhibitors and emerging approaches like PROTACs and gene therapy, show promise for correcting cellular imbalances and re...

SourceChinese Medical Journals Publishing House Co., Ltd.·JournalChinese Medical Journal·TypeLiterature review·DateApr 1, 2026

AstraZeneca joins Robert A. Winn Excellence in Clinical Trials Award Program as Funding Partner

The Robert A. Winn Excellence in Clinical Trials Award Program has partnered with AstraZeneca to support five medical students participating in the Winn Clinical Investigator Pathway Program (Winn CIPP). The program provides immersive training, mentorship, and hands-on experience to prepare students for careers in clinical research.

Study illuminates benefits of red blood cell exchange in severe babesiosis

A multicenter study found that red blood cell exchange transfusion significantly improves clinical outcomes for patients hospitalized with severe babesiosis, a potentially life-threatening tick-borne infection. The procedure was associated with substantially lower risk of in-hospital death or readmission.

SourceBrigham and Women's Hospital·JournalJAMA Internal Medicine·TypeRandomized controlled/clinical trial·DateMar 30, 2026

Minimally invasive valve repair reduces heart failure hospitalizations in patients with severe tricuspid regurgitation

A minimally invasive procedure using a clip to repair the valve significantly reduced heart failure hospitalizations by 40% in patients with severe tricuspid regurgitation. The study, presented at the American College of Cardiology's Annual Scientific Session, showed improved long-term outcomes without crossover between treatment groups.

Microaxial flow pump does not improve outcomes for high-risk heart attack patients without cardiogenic shock

A new trial found that using a microaxial flow pump before and during cardiac stenting procedures for high-risk heart attack patients with severe heart attacks did not reduce heart damage. The study, published in the Journal of the American College of Cardiology, also showed increased bleeding complications.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalJournal of the American College of Cardiology·TypeRandomized controlled/clinical trial·DateMar 28, 2026

TENS improves pain and fatigue in fibromyalgia

A new study led by University of Iowa Health Care researchers found that TENS reduced movement-evoked pain and fatigue in patients with fibromyalgia, with effects lasting for at least six months. The treatment was also shown to be safe, effective, inexpensive, and readily available.

SourceUniversity of Iowa Health Care·JournalJAMA Network Open·TypeRandomized controlled/clinical trial·DateMar 27, 2026

New study finds common blood pressure drug boosts cancer treatment

A new study found that the common blood pressure medication telmisartan can significantly enhance the cancer-killing activity of olaparib, potentially expanding its use to many more patients. Telmisartan made tumors more vulnerable to PARP inhibitors, even when they lacked specific DNA repair defects.

SourceDartmouth Health·JournalJournal for ImmunoTherapy of Cancer·TypeExperimental study·DateMar 25, 2026

Can exercise help chemo brain? New research adds promising results

A new study suggests that exercise can improve mental sharpness and reduce cognitive decline in cancer patients undergoing chemotherapy. Researchers found that patients who exercised while on chemotherapy maintained their daily step goals and reported improved mental clarity, while those who did not exercise experienced significant dec...

SourceUniversity of Rochester Medical Center·JournalJournal of the National Comprehensive Cancer Network·TypeRandomized controlled/clinical trial·DateMar 13, 2026

Gene therapy for Duchenne muscular dystrophy: Genethon confirms two-year efficacy in patients treated with its drug candidate GNT0004 at therapeutic dose in the first phase of its clinical trial

Genethon's GNT0004 gene therapy shows long-term efficacy in patients with Duchenne muscular dystrophy, maintaining clinical efficacy and safety at two years. The trial included 72 boys aged 6-10 with retained walking ability, treated with GNT0004 at a therapeutic dose.

Atamyo Therapeutics presents promising results in the first patients treated with its ATA-200 gene therapy in the clinical trial targeting LGMD-R5 limb-girdle muscular dystrophy

The company's ATA-200 gene therapy has shown safety, pharmacodynamics, and efficacy results in the first patients treated, offering hope for children with LGMD-R5. The therapy delivers a normal copy of the γ-sarcoglycan gene and has been awarded Orphan Drug Designation in the US and Europe.

Acoziborole Winthrop, developed by DNDi and Sanofi, receives European Medicines Agency positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

The European Medicines Agency has granted a positive opinion to Acoziborole Winthrop as a single-dose oral treatment for both early- and advanced-stage gambiense sleeping sickness in adults and adolescents. The medicine, co-developed by DNDi and Sanofi, could provide a significant advance over current therapies.

Aspirin not a quick fix for preventing bowel cancer

Daily aspirin use offers no quick or reliable way to prevent bowel cancer in the general population, increasing risk of serious bleeding. However, it may have potential long-term benefits for people at high genetic risk of colorectal cancer.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateFeb 25, 2026

Barshop Institute to receive up to $38 million from ARPA-H, anchoring UT San Antonio as a national leader in aging and healthy longevity science

The Barshop Institute will conduct the VITAL-H trial, evaluating the repurposing of FDA-approved medications to delay age-related health decline in generally healthy middle-aged adults. The trial aims to preserve everyday abilities during a critical window of midlife aging.

Evidence behind intermittent fasting for weight loss fails to match hype

A new Cochrane review suggests that intermittent fasting may not be an effective strategy for weight loss in overweight or obese adults. The study found no meaningful difference in weight loss between intermittent fasting and traditional dietary advice or doing nothing, highlighting the need for more research into this area.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateFeb 15, 2026

Validation of SOFA-2 score in sepsis and exploration of its extension with additional immune markers

The study validates the use of SOFA-2 in sepsis care and research, demonstrating its ability to identify clinically meaningful organ dysfunction. The findings suggest that incorporating immune markers may not improve predictive performance, highlighting the biological complexity of sepsis.

SourceJournal of Intensive Medicine·JournalJournal of Intensive Medicine·TypeObservational study·DateFeb 3, 2026

Unexpected partial recovery of natural vision observed after intracortical microstimulation in a blind patient

A blind patient partially recovered natural vision through electrical stimulation of the visual cortex, independent of the implant. The recovery was sustained over time and remained even after the device was removed, suggesting individual factors may have contributed to this outcome.

SourceUniversidad Miguel Hernandez de Elche·JournalBrain Communications·TypeExperimental study·DateFeb 3, 2026

Detecting early-stage cancers with a new blood test measuring epigenetic instability

Researchers at Johns Hopkins Kimmel Cancer Center have developed a novel liquid biopsy approach to identify early-stage cancers by measuring DNA methylation patterns. The Epigenetic Instability Index (EII) successfully distinguished patients with early-stage lung and breast cancers from healthy individuals, showing promise in detecting...

SourceJohns Hopkins Medicine·JournalClinical Cancer Research·DateFeb 2, 2026

Alliance Foundation Trials phase III PATINA study results published in the New England Journal of Medicine

The phase III PATINA study demonstrated that adding CDK4/6 inhibitor palbociclib to standard maintenance therapy significantly prolongs progression-free survival by more than 15 months compared to standard therapy alone. The study found a meaningful improvement in median PFS with no new signals.

SourceAlliance for Clinical Trials in Oncology·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJan 28, 2026

Most common methods of inducing labour similarly effective

A new review of over 100 clinical trials found that 13 common labor induction methods are similarly effective, with low-dose vaginal misoprostol being the most commonly used and safest. However, some methods showed better success rates for specific outcomes, such as oxytocin with amniotomy for achieving vaginal birth within 24 hours.

SourceCochrane·JournalCochrane Database of Systematic Reviews·TypeSystematic review·DateJan 26, 2026

Study shows younger children experience persistent symptoms following concussion

A new study from Nationwide Children's Hospital finds that similar to older children and adults, about one fourth of children under six years old who experience a concussion will develop prolonged symptoms. Younger children are more likely to sustain brain injuries due to their size differences and weaker muscles.

SourceNationwide Children's Hospital·JournalPEDIATRICS·TypeData/statistical analysis·DateJan 26, 2026

ISSCR develops roadmap to accelerate pluripotent stem cell-derived therapies to patients

The ISSCR has released a comprehensive roadmap for developing pluripotent stem cell-derived therapies, outlining critical scientific, manufacturing, and regulatory guidance. The Best Practices document provides a risk-based, end-to-end development strategy to support informed decision-making across seven essential areas.

SourceInternational Society for Stem Cell Research·JournalStem Cell Reports·DateJan 22, 2026

Alliance trial reveals gene variant may affect prostate cancer drug efficacy

A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...

SourceAlliance for Clinical Trials in Oncology·JournalClinical and Translational Science·TypeExperimental study·DateJan 14, 2026